A second honeymoon for Parkinson's disease?

C. Tanner
DOI: https://doi.org/10.1056/NEJMe1214913
IF: 158.5
2013-02-13
New England Journal of Medicine
Abstract:Parkinson's disease is a chronic, progressively disabling neurodegenerative disorder that occurs late in life, causing motor, autonomic, emotional, and cognitive symptoms. The cost of Parkinson's disease is substantial, including reduced quality of life, lost productivity, and increased health care expenditures. The number of persons with Parkinson's disease worldwide is, conservatively, expected to nearly double by 2030, owing to overall aging of the population.1 Effective treatments for Parkinson's disease are an imperative. Medical therapy for Parkinson's disease is most effective in treating the motor symptoms of resting tremor, bradykinesia, and rigidity. Levodopa remains the most effective current treatment for motor symptoms; . . .
What problem does this paper attempt to address?